245 related articles for article (PubMed ID: 33196081)
1. Lagged Relationships Among Chemotherapy-Induced Peripheral Neuropathy, Sleep Quality, and Physical Activity During and After Chemotherapy.
Bulls HW; Hoogland AI; Small BJ; Kennedy B; James BW; Arboleda BL; Shahzad MMK; Gonzalez BD; Jim HSL
Ann Behav Med; 2021 Aug; 55(9):844-852. PubMed ID: 33196081
[TBL] [Abstract][Full Text] [Related]
2. A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer.
Bulls HW; Hoogland AI; Kennedy B; James BW; Arboleda BL; Apte S; Chon HS; Small BJ; Gonzalez BD; Jim HSL
Gynecol Oncol; 2019 Feb; 152(2):310-315. PubMed ID: 30558975
[TBL] [Abstract][Full Text] [Related]
3. Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry.
Bonhof CS; Trompetter HR; Vreugdenhil G; van de Poll-Franse LV; Mols F
Support Care Cancer; 2020 Dec; 28(12):5933-5941. PubMed ID: 32281032
[TBL] [Abstract][Full Text] [Related]
4. Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy.
Menant JC; Goldstein D; Au K; Trinh T; van Schooten KS; McCrary JM; Harris CA; Forster BC; Park SB
Gait Posture; 2021 Sep; 89():178-185. PubMed ID: 34320441
[TBL] [Abstract][Full Text] [Related]
5. The Physical Consequences of Chemotherapy-Induced Peripheral Neuropathy.
Tofthagen CS; Cheville AL; Loprinzi CL
Curr Oncol Rep; 2020 Apr; 22(5):50. PubMed ID: 32323068
[TBL] [Abstract][Full Text] [Related]
6. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.
Mols F; van de Poll-Franse LV; Vreugdenhil G; Beijers AJ; Kieffer JM; Aaronson NK; Husson O
Eur J Cancer; 2016 Dec; 69():28-38. PubMed ID: 27814471
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
8. Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors.
Wong ML; Cooper BA; Paul SM; Abrams G; Topp K; Kober KM; Chesney MA; Mazor M; Schumacher MA; Conley YP; Levine JD; Miaskowski C
Support Care Cancer; 2019 Oct; 27(10):3905-3912. PubMed ID: 30770977
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-Induced Peripheral Neuropathy (CIPN) as a Predictor of Decreased Quality of Life in Testicular Germ Cell Tumor Survivors.
Orszaghova Z; Galikova D; Lesko P; Obertova J; Rejlekova K; Sycova-Mila Z; Palacka P; Kalavska K; Svetlovska D; Mladosievicova B; Mardiak J; Mego M; Chovanec M
Clin Genitourin Cancer; 2024 Jun; 22(3):102067. PubMed ID: 38555680
[TBL] [Abstract][Full Text] [Related]
10. Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy.
Mizrahi D; Goldstein D; Trinh T; Li T; Timmins HC; Harrison M; Marx GM; Hovey EJ; Lewis CR; Friedlander M; Park SB
Asia Pac J Clin Oncol; 2023 Feb; 19(1):243-249. PubMed ID: 35879821
[TBL] [Abstract][Full Text] [Related]
11. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
[TBL] [Abstract][Full Text] [Related]
12. Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Cao A; Cartmel B; Li FY; Gottlieb LT; Harrigan M; Ligibel JA; Gogoi R; Schwartz PE; Esserman DA; Irwin ML; Ferrucci LM
JAMA Netw Open; 2023 Aug; 6(8):e2326463. PubMed ID: 37526937
[TBL] [Abstract][Full Text] [Related]
13. Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy.
Knoerl R; Weller E; Halpenny B; Berry D
BMC Cancer; 2018 Dec; 18(1):1203. PubMed ID: 30514351
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
[TBL] [Abstract][Full Text] [Related]
15. Impact of exercise on chemotherapy-induced peripheral neuropathy in survivors with post-treatment primary breast cancer.
Saint K; Nemirovsky D; Lessing A; Chen Y; Yang M; Underwood WP; Galantino ML; Jones LW; Bao T
Breast Cancer Res Treat; 2024 Aug; 206(3):667-675. PubMed ID: 38713289
[TBL] [Abstract][Full Text] [Related]
16. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.
Alberti P; Rossi E; Cornblath DR; Merkies IS; Postma TJ; Frigeni B; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Faber CG; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Valsecchi MG; Cavaletti G;
Ann Oncol; 2014 Jan; 25(1):257-64. PubMed ID: 24256846
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-Induced Peripheral Neuropathy Detection via a Smartphone App: Cross-sectional Pilot Study.
Chen CS; Kim J; Garg N; Guntupalli H; Jagsi R; Griggs JJ; Sabel M; Dorsch MP; Callaghan BC; Hertz DL
JMIR Mhealth Uhealth; 2021 Jul; 9(7):e27502. PubMed ID: 36260403
[TBL] [Abstract][Full Text] [Related]
18. Identifying trajectories and predictors of chemotherapy-induced peripheral neuropathy symptoms, physical functioning, and falls across treatment and recovery in adults treated with neurotoxic chemotherapy: the PATTERN observational study protocol (NCT05790538).
Winters-Stone KM; Krasnow SM; Horak FB; Mancini M; Cameron MH; Dieckmann NF; Stoyles SA; Roeland EJ
BMC Cancer; 2023 Nov; 23(1):1087. PubMed ID: 37946117
[TBL] [Abstract][Full Text] [Related]
19. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
20. Reflexology in the management of chemotherapy induced peripheral neuropathy: A pilot randomized controlled trial.
Kurt S; Can G
Eur J Oncol Nurs; 2018 Feb; 32():12-19. PubMed ID: 29353627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
